US20050042761A1 - Method for identifying at risk cardiovascular disease patients - Google Patents

Method for identifying at risk cardiovascular disease patients Download PDF

Info

Publication number
US20050042761A1
US20050042761A1 US10/959,656 US95965604A US2005042761A1 US 20050042761 A1 US20050042761 A1 US 20050042761A1 US 95965604 A US95965604 A US 95965604A US 2005042761 A1 US2005042761 A1 US 2005042761A1
Authority
US
United States
Prior art keywords
ldl
hdl
ldlc
ldliiia
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/959,656
Inventor
David Shewmake
Frank Ruderman
Christopher Boggess
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Berkeley Heartlab Inc
Original Assignee
Berkeley Heartlab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berkeley Heartlab Inc filed Critical Berkeley Heartlab Inc
Priority to US10/959,656 priority Critical patent/US20050042761A1/en
Publication of US20050042761A1 publication Critical patent/US20050042761A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • This invention is in the field of cardiovascular healthcare management and patient treatment.
  • LDL low density lipoprotein
  • the invention utilizes the health care management system described in WO 01/41037A3 to study data from patient populations for cardiovascular risk factors especially those factors related to LDL and HDL subclass.
  • WO 01/41037AC is incorporated herein in its entirety.
  • the text, Heart Disease Breakthrough, by Thomas Yannios, M.D. John Wiley & Son, Inc., New York, 1999 discusses management of heart disease and the role of HDL and LDL subclasses and is incorporated herein by reference.
  • LDL and HDL subclass information that is not available from NCEP risk factor data.
  • the invention permits the identification of patients with healthy low density lipoprotein concentration (LDLC) and high density lipoprotein concentration (HDLC) levels who have an undesirable small dense LDL trait and deficient reverse cholesterol transport system.
  • LDLC low density lipoprotein concentration
  • HDLC high density lipoprotein concentration
  • LDL III a+b permits the identification of patients who are in need of therapeutic lifestyle changes and drug therapy which are not evident from NCEP guidelines based on a conventional panel of lipid assays.
  • HDL 2b values can be used to identify patients in need of lifestyle change or drug therapy. LDL III a+b and HDL 2b values combined is a powerful tool for identifying patients who need treatment which NCEP data indicate are not in need of treatment.
  • the invention therefore encompasses a method for identifying patients with normal NCEP lipid levels who are in need of treatment for cardiovascular disease comprising measuring one or more LDL or HDL particle subtraction levels and identifying abnormal LDL or HDL subtraction levels.
  • LDL III a+b are the preferred LDL subclasses to be measured and HDL 2b is the preferred HDL subclass.
  • Other factors such as lipoprotein (a) (Lp(a)), triglycerides, and homocysteine also provide highly useful information.
  • LDL and HDL subclasses are determined by gradient gel electrophoresis (GGE), NMR, ultracentrifugation, or ion mobility analysis.
  • Database search criteria was set at two LDL levels: patients with LDLC ⁇ 130 and patients with LDLC ⁇ 100.
  • Another aspect of the invention involves utilizing the HDL 2b subclass data in the database. If the LDLC ⁇ 100 database is used, the invention provides a test for hard to treat or difficult patients. But, the LDL ⁇ 100 database also illustrates that just driving down LDLC is not always the solution. On the other hand, the LDL ⁇ 130 database may seem too conservative because the NCEP goal is 100 for patients with CHD or CHD risk equivalents, but it does adhere to the population of patients who have family history or haven't been treated and need to establish a baseline to monitor therapy. The four variable search of patients with LDLC ⁇ 130, HDL>40, an LDL IIIa+b value, and/or an HDL 2b value exhibits similar results from the LDLC ⁇ 130 database.
  • the LDLC ⁇ 130 and HDL>40 are at “healthy” levels according to NCEP, but the same verdict is displayed as the above database search. 70% of the population has an elevated LDL IIIa+b. When HDL 2b is added to the equation, the percentage of patients with both abnormal LDL IIIa+b and HDL 2b values slightly lessen to 59%. Thus, about 6 out of 10 patients with “healthy” LDLC and HDLC levels express both the small dense LDL trait and deficient reverse cholesterol transport system.
  • the other four variable search of patients with LDLC ⁇ 100, HDL>40, an LDL IIIa+b value, and/or an HDL 2b value exhibits similar results from its database sibling.
  • the concomitant risk factors of elevated LDLIIIa+b and deficient HDL 2b occur 91% of the time.

Abstract

The invention provides a method for identifying patients with normal NCEP lipid levels who are in need of treatment for cardiovascular disease comprising measuring one or more LDL or HDL particle subclass levels and identifying abnormal LDL or HDL subclass levels. LDL III a+b and HDL 2b are preferred subclasses.

Description

    FIELD OF THE INVENTION
  • This invention is in the field of cardiovascular healthcare management and patient treatment.
    • BACKGROUND OF THE INVENTION
  • According to the National Cholesterol Education Program (NCEP) guidelines, low density lipoprotein (LDL) cholesterol goals and criteria for Therapeutic Lifestyle Changes and Drug Therapy in different risk categories are as follows:
    LDL level to ini- LDL level to
    Risk tiate Therapeutic consider Drug
    Category LDL Goal Lifestyle Changes Therapy
    CHD or CHD <100 mg/dL 100 mg/dL 130 mg/dL
    Risk (10 yr risk 10-20%)
    Equivalents 160 mg/dL
    (10-yr risk <10%)
    2+ Risk <130 mg/dL 130 mg/dL 130 mg/dL
    Factors (10 yr risk 10-20%)
    160 mg/dL
    (10-yrrisk <10%)
    0-1 Risk <160 mg/dL 160 mg/dL 190 mg/dL
    Factor
  • The invention utilizes the health care management system described in WO 01/41037A3 to study data from patient populations for cardiovascular risk factors especially those factors related to LDL and HDL subclass. WO 01/41037AC is incorporated herein in its entirety. The text, Heart Disease Breakthrough, by Thomas Yannios, M.D. John Wiley & Son, Inc., New York, 1999 discusses management of heart disease and the role of HDL and LDL subclasses and is incorporated herein by reference.
    • SUMMARY OF THE INVENTION
  • In analyzing LDL and HDL subclass data from more than 65,000 cardiovascular patients, it has been found that indicia for patient treatment can be derived from LDL and HDL subclass information that is not available from NCEP risk factor data. Thus, the invention permits the identification of patients with healthy low density lipoprotein concentration (LDLC) and high density lipoprotein concentration (HDLC) levels who have an undesirable small dense LDL trait and deficient reverse cholesterol transport system. For example, it has unexpectedly been found that the determination of LDL III a+b permits the identification of patients who are in need of therapeutic lifestyle changes and drug therapy which are not evident from NCEP guidelines based on a conventional panel of lipid assays. Similarly HDL 2b values can be used to identify patients in need of lifestyle change or drug therapy. LDL III a+b and HDL 2b values combined is a powerful tool for identifying patients who need treatment which NCEP data indicate are not in need of treatment.
  • More particularly, it has been determined that cardiovascular patients with LDL III a+b levels, small dense LDL particles, of about 15% or more are in need of more aggressive cardiovascular healthcare management, i.e., lifestyle changes and drug therapy. This LDL III a+b measurement identifies about 40% of patients in need of treatment that are missed by only using NCEP guidelines. Thus, the NCEP guidelines for treatment which are based on the basic lipid panel described above are not capable of determining cardiovascular risk in a significant subpopulation of patients and result in not treating at risk cardiovascular patients.
  • The invention therefore encompasses a method for identifying patients with normal NCEP lipid levels who are in need of treatment for cardiovascular disease comprising measuring one or more LDL or HDL particle subtraction levels and identifying abnormal LDL or HDL subtraction levels.
  • LDL III a+b are the preferred LDL subclasses to be measured and HDL 2b is the preferred HDL subclass. Other factors such as lipoprotein (a) (Lp(a)), triglycerides, and homocysteine also provide highly useful information. LDL and HDL subclasses are determined by gradient gel electrophoresis (GGE), NMR, ultracentrifugation, or ion mobility analysis.
    • DETAILED DESCRIPTION OF THE INVENTION
  • Database Statistics:
  • There are 65,536 patients in the database of which 51% (33,463) have LDLC<130 mg/dL and 44% (20,149) have levels of LDLC<100 mg/dL. Furthermore, 47% (31,102) of all patients in the database have LDL IIIa+b measurements.
  • Methods:
  • Database search criteria was set at two LDL levels: patients with LDLC<130 and patients with LDLC<100.
  • Results:
  • Of the patients with LDLC<130 and measured LDL—by gradient gel electrophoresis (GGE), 74% had an LDL IIIa+b 15% (see below)—a value documented to raise cardiovascular risk by 3-fold.
  • A. LDLC<130 mg/dL=33,463 patients (51% of total volume)
      • 1. LDLC<130 mg/dL with LDLIIIa+b 15%=74%
      • 2. LDLC<130 mg/dL with LDLIIIa+b 20%=55%
      • 3. Pheno A=19,653 or 44%
      • 4. Pheno AB=5,568 or 17%
      • 5. Pheno B=13,173 or 39%
      • **Note: Each database has a limiting population factor. The above search only uses two variables and the limiting factor is LDLIIIa+b (n=18,797). Each introduction of a new variable limits the population of the result.
  • Of the patients with LDLC<100 and measured LDL-GGE, 85% of them had a LDL IIIa+b 15%(see below).
  • B. LDLC<100 mg/dL=20,149 patients (44% of total volume)
      • 1. LDLC<100 mg/dL with LDLHIa+b 15%=85%
      • 2. LDLC<100 mg/dL with LDLHIa+b 20%=70%
      • 3. Pheno A=8,411 or 42%
      • 4. Pheno AB=3,431 or 17%
      • 5. Pheno B=8,307 or 41%
  • In either case, patients considered to be under “control” and thought not to require further treatment by NCEP guidelines had a preponderance of small, dense atherogenic particles and required varying degrees of aggressive treatment.
  • Another aspect of the invention involves utilizing the HDL 2b subclass data in the database. If the LDLC<100 database is used, the invention provides a test for hard to treat or difficult patients. But, the LDL<100 database also illustrates that just driving down LDLC is not always the solution. On the other hand, the LDL<130 database may seem too conservative because the NCEP goal is 100 for patients with CHD or CHD risk equivalents, but it does adhere to the population of patients who have family history or haven't been treated and need to establish a baseline to monitor therapy. The four variable search of patients with LDLC<130, HDL>40, an LDL IIIa+b value, and/or an HDL 2b value exhibits similar results from the LDLC<130 database.
  • C. LDLC<130 mg/dL+HDLC>40 mg/dL=13,810
      • 1. (C) with LDLIIIa+b 15%=70%
      • 2. (C) with LDLIIIa+b 20%=43%
      • 3. (C) with HDL 2b>20%=56%
      • 4. (C) with LDLIIIa+b 15%+HDL 2b>20%=59%
      • 5. (C) with LDLIIIa+b 20%+HDL 2b>20%=40%
  • If it is assumed these patients have 2+risk factors, the LDLC<130 and HDL>40 are at “healthy” levels according to NCEP, but the same verdict is displayed as the above database search. 70% of the population has an elevated LDL IIIa+b. When HDL 2b is added to the equation, the percentage of patients with both abnormal LDL IIIa+b and HDL 2b values slightly lessen to 59%. Thus, about 6 out of 10 patients with “healthy” LDLC and HDLC levels express both the small dense LDL trait and deficient reverse cholesterol transport system.
  • The other four variable search of patients with LDLC<100, HDL>40, an LDL IIIa+b value, and/or an HDL 2b value exhibits similar results from its database sibling. The concomitant risk factors of elevated LDLIIIa+b and deficient HDL 2b occur 91% of the time.
  • D. LDLC<100 mg/dL+HDLC>40 mg/dL=11,334
      • 1. (D) with LDLIIIa+b 15%=84%
      • 2. (D) with LDLIIIa+b 20%=60%
      • 3. (D) with HDL 2b>20%=53%
      • 4. (D) with LDLIIIa+b 15%+HDL 2b>20%=91%
      • 5. (D) with LDLIIIa+b 20%+HDL 2b>20%=68%
  • Physicians who have patients with an LDLC value under control (<100) often conclude that they need no further information for treating the patient. This is not the case (See B), 85% of the population with LDL IIIa+b values were elevated and were in need of treatment.
  • There are several other aspects of the invention derived from the database analysis such as 61% of patients with LDL<100 or LDL<130 and TG<150 still have deficient or abnormal HDL 2b values (LDLC under control and triglyceride metabolism working fine, but unapparent deficient reverse cholesterol transport). All of these newly discovered relationships are summarized below in their respective database (LDLC<130 or LDLC<100).
  • Database Informatics (LDL<130 mg/dL)
    • (Total Database Volume: 65,536)
    • (Total of patients with LDL IIIa+b values: 31,102 (47%))
      A. LDLC<130 mg/dL=33,463 patients (73% of total volume
      • 1. LDLC<130 mg/dL with LDLHIa+b 15%=74%
      • 2. LDLC<130 mg/dL with LDLIIIa+b 20%=55%
        • a. Pheno A=19,653 or 43%
        • b. Pheno AB=5,568 or 17%
        • c. Pheno B=13,173 or 39%
          B. LDLC<130 mg/dL+HDLC>40 mg/dL=13,810
      • 1. (B) with LDLIIIa+b 15%=70%
      • 2. (B) with LDLIIIa+b 20%=43%
      • 3. (B) with HDL 2b>20%=56%
      • 4. (B) with LDLIIIa+b 15%+HDL 2b>20%=59%
      • 5. (B) with LDLIIIa+b 20%+HDL 2b>20%=40%
        C. LDLC<130 mg/dL+HDL2b<20%=13,168
      • 1.(C) with LDLIIIa+b 15%=86%
      • 2.(C) with LDLIIIa+b 20%=68%
        D. LDLC<130 mg/dL+HDL2b>20%=3,642
      • 1. (D) with LDLIIIa+b 15%=77%
      • 2. (D) with LDLIIIa+b 20%=38%
        E. LDLC<130 mg/dL+HDL2b>20%+Lp(a)>20 mg/dL=1,417
      • 1. (E) with LDLIIIa+b 15%=77%
      • 2. (E) with LDLIIIa+b 20%=38%
        F. LDLC<130 mg/dL+Lp(a)>20 mg/dL=10,587
      • 1. (F) with LDLIIIa+b 15%=73%
      • 2. (F) with LDLIIIa+b 20%=52%
        G. LDLC<130 mg/dL+HDLC>40 mg/dL=11,226
      • 1. (G) with LDLIIIa+b 15%=70%
      • 2. (G) with LDLIIIa+b 20%=43%
        H. LDLC<130 mg/dL+TG<150 mg/dL=28,270
      • 1. (H) with LDLIIIa+b 15%=70%
      • 2. (H) with LDLIIIa+b 20%=42%
      • 3. (H) with HDL 2b<20%=62%
        I. LDLC<130 mg/dL+TG<180 mg/dL=24,796
      • 1. (L) with LDLIIIa+b 15%=72%
      • 2. (L) with LDLIIIa+b 20%=46%
        J. LDLC<130 mg/dL+TG<180 mg/dL+HDL>40 mg/dL=16,723
      • 1.(J) with LDLIIIa+b 15%=70%
      • 2.(J) with LDLIIIa+b 20%=30%
        K. LDLC<130 mg/dL+TG<180 mg/dL+HDL2b>20%=3,549
      • 1. (K) with LDLIIIa+b 15%=68%
      • 2. (K with LDLIIIa+b 20%=37%
        Database Informatics (LDLC<100 mg/dL)
    • (Total Database Volume: 65,536)
    • (Total of patients with LDL IIIa+b values: 31,102 (47%))
      A. LDLC<100 mg/dL=20,149 patients (44% of total volume)
      • 1. LDLC<100 mg/dL with LDLIIIa+b 15%=85%
      • 2. LDLC<100 mg/dL with LDLIIIa+b 20%=70%
        • a. Pheno A=8,411 or 42%
        • b. Pheno AB=3,431 or 17%
        • c. Pheno B=8,307 or 41%
          B. LDLC<100 mg/dL+HDLC>40 mg/dL=11,334
      • 1. (B) with LDLIIIa+b 15%=84%
      • 2. (B) with LDLIIIa+b 20%=60%
      • 3. (B) with HDL2b>20%=53%
      • 4. (B) with LDLIIIa+b 15%+HDL 2b>20%=91%
      • 5. (B) with LDLIIIa+b 20%+HDL 2b>20%=68%
        C. LDLC<100 mg/dL+HDL2b>20%=2,772
      • 1. (C) with LDLIIIa+b 15%=88%
      • 2. (C) with LDLIIIa+b 20%=58%
        D. LDLC<100 mg/dL+HDL2b<20%=5,906
      • 1.(D) with LDLIIIa+b 15%=94%
      • 2.(D) with LDLIIIa+b 20%=81%
        E. LDLC<100 mg/dL+HDL2b>20%+Lp(a)>20 mg/dL=901
      • 1.(E) with LDLIIIa+b 15%=92%
      • 2.(E) with LDLIIIa+b 20%=63%
        F. LDLC<100 mg/dL+Lp(a)>20 mg/dL=6,024
      • 1.(F) with LDLIIIa+b. 15%=86%
      • 2.(F) with LDLIIIa+b 20%=70%
        G. LDLC<100 mg/dL+TG<180 mg/dL=14,414
      • 1.(G) with LDLIIIa+b 15%=84%
      • 2.(G) with LDLIIIa+b 20%=62%
        H. LDLC<100 mg/dL+TG<150 mg/dL=12,513
      • 1.(H) with LDLIIIa+b 15%=84%
      • 2.(H) with LDLIIIa+b 20%=60%
      • 3.(H) with HDL 2b<20%=61%
        I. LDLC<100 mg/dL+TG<150 mg/dL+Lp(a)>20 mg/dL=4117
      • 1.(I) with LDLIIIa+b 15%=85%
      • 2.(I) with LDLIIIa+b 20%=61%
  • The above examples illustrate the present invention and are not intended to limit it in spirit or scope.

Claims (14)

1. A method for identifying patients with normal NCEP lipid levels who are in need of treatment for cardiovascular disease comprising measuring one or more LDL or HDL particle subclass levels and identifying abnormal LDL or HDL subclass levels.
2. The method of claim 1 wherein the subclass is LDL III a+b.
3. The method of claim 2 wherein the abnormal level of LDLIII a+b is a level above 15% of the LDL particles.
4. The method of claim 1 wherein the subclass is HDL 2b.
5. The method of claim 4 wherein the abnormal level of HDL 2b is a level below 20% of the HDL particles.
6. A method for identifying a human subject in need of cardiovascular disease treatment comprising identifying subjects having LDL III a+b levels of about 15% or more of the LDL particles.
7. The method of claim 6 wherein HDL 2b is also measured.
8. The method according to claim 6 wherein the human subject has an LDLC<130 mg/dl.
9. The method according to claim 6 wherein the human subject has an LDLC<130 mg/dl.
10. The method according to claim 6 wherein the human subject has HDL 2b<20% of HDL particles.
11. The method of claim 6 wherein the LDL values are measured by gradient gel electrophoresis.
12. A method for identifying cardiovascular patients with LDL levels below the levels indicated by NCEP for initiation of therapeutic lifestyle changes or to initiate drug therapy comprising measure the portion of small LDL particles to total LDL particles in the patient's blood serum.
13. The method of claim 1 wherein the LDL and HDL subclass are determined by linear gel electrophoresis, gradient gel electrophoresis, ultracentrifuge, or ion mobility analysis.
14. The method of claim 1 wherein the LDL and HDL subclass are measured by gradient gel electrophoresis.
US10/959,656 2002-04-12 2004-10-06 Method for identifying at risk cardiovascular disease patients Abandoned US20050042761A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/959,656 US20050042761A1 (en) 2002-04-12 2004-10-06 Method for identifying at risk cardiovascular disease patients

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/122,081 US6812033B2 (en) 2002-04-12 2002-04-12 Method for identifying risk cardiovascular disease patients
US10/959,656 US20050042761A1 (en) 2002-04-12 2004-10-06 Method for identifying at risk cardiovascular disease patients

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/122,081 Continuation US6812033B2 (en) 2002-04-12 2002-04-12 Method for identifying risk cardiovascular disease patients

Publications (1)

Publication Number Publication Date
US20050042761A1 true US20050042761A1 (en) 2005-02-24

Family

ID=28790484

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/122,081 Expired - Lifetime US6812033B2 (en) 2002-04-12 2002-04-12 Method for identifying risk cardiovascular disease patients
US10/959,656 Abandoned US20050042761A1 (en) 2002-04-12 2004-10-06 Method for identifying at risk cardiovascular disease patients

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/122,081 Expired - Lifetime US6812033B2 (en) 2002-04-12 2002-04-12 Method for identifying risk cardiovascular disease patients

Country Status (1)

Country Link
US (2) US6812033B2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060183234A1 (en) * 2003-10-23 2006-08-17 Otvos James D Methods, systems and computer programs for assessing chd risk using adjusted ldl particle number measurements
US20080050740A1 (en) * 2006-06-23 2008-02-28 Cassidy Pamela M Nutritional and Exercise Plan Based On A Person's Individual Genetic APO E Genotype

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7416895B2 (en) * 2002-06-21 2008-08-26 Berkeley Heartlab, Inc. Method for identifying at risk cardiovascular disease patients
US20040043496A1 (en) * 2002-06-21 2004-03-04 Berkeley Heartlab, Inc. Method for identifying patients who will require multiple invasive cardiovascular procedures
JP4643445B2 (en) 2002-11-12 2011-03-02 ベクトン，ディッキンソン アンド カンパニー Diagnosis of sepsis or SIRS using biomarker profiles
US7226792B2 (en) * 2003-05-27 2007-06-05 Berkeley Heartlab, Inc. Method for selecting an optimal diet and exercise regimen based on LDL and HDL subclass determination
JP2009510436A (en) * 2005-09-29 2009-03-12 バークレー ハートラボ Method for quantitatively determining the number of LDL particles in the distribution of LDL cholesterol subfraction
WO2010009269A2 (en) * 2008-07-15 2010-01-21 Piedmont Healthcare, Inc. Method for coronary artery disease risk assessment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925229A (en) * 1996-05-03 1999-07-20 The Regents Of The University Of California Low density lipoprotein fraction assay for cardiac disease risk
US6576471B2 (en) * 1999-02-26 2003-06-10 Liposcience, Inc. Methods, systems, and computer program products for analyzing and presenting NMR lipoprotein-based risk assessment results

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925229A (en) * 1996-05-03 1999-07-20 The Regents Of The University Of California Low density lipoprotein fraction assay for cardiac disease risk
US6576471B2 (en) * 1999-02-26 2003-06-10 Liposcience, Inc. Methods, systems, and computer program products for analyzing and presenting NMR lipoprotein-based risk assessment results

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060183234A1 (en) * 2003-10-23 2006-08-17 Otvos James D Methods, systems and computer programs for assessing chd risk using adjusted ldl particle number measurements
US7790465B2 (en) * 2003-10-23 2010-09-07 Liposcience, Inc. Methods, systems and computer programs for assessing CHD risk using adjusted LDL particle number measurements
US20080050740A1 (en) * 2006-06-23 2008-02-28 Cassidy Pamela M Nutritional and Exercise Plan Based On A Person's Individual Genetic APO E Genotype

Also Published As

Publication number Publication date
US20030194812A1 (en) 2003-10-16
US6812033B2 (en) 2004-11-02

Similar Documents

Publication Publication Date Title
Savino et al. Handgrip strength predicts persistent walking recovery after hip fracture surgery
Moayyeri et al. Cohort Profile: TwinsUK and healthy ageing twin study
Delalla et al. Ultracentrifugal studies of high density serum lipoproteins in clinically healthy adults
Huddleston et al. Myocardial infarction after hip fracture repair: a population‐based study
Rozenberg et al. Thoracic muscle cross‐sectional area is associated with hospital length of stay post lung transplantation: a retrospective cohort study
Sowa et al. Associations between serum biomarkers and pain and pain‐related function in older adults with low back pain: a pilot study
Sung et al. Lipoprotein (a), metabolic syndrome and coronary calcium score in a large occupational cohort
Berry et al. Relationship of serum markers of cartilage metabolism to imaging and clinical outcome measures of knee joint structure
Mok et al. Estimating body composition in children with Duchenne muscular dystrophy: comparison of bioelectrical impedance analysis and skinfold-thickness measurement
Cummings et al. The Study of Muscle, Mobility and Aging (SOMMA): a unique cohort study about the cellular biology of aging and age-related loss of mobility
US20090188796A1 (en) Method For Identifying At Risk Cardiovascular Disease Patients
Peng et al. Potential biomarkers for early diagnosis of acute aortic dissection
Bokshan et al. Inpatient costs and blood transfusion rates of sarcopenic patients following thoracolumbar spine surgery
Vranken et al. The phenotype of patients with a recent fracture: a literature survey of the fracture liaison service
US6812033B2 (en) Method for identifying risk cardiovascular disease patients
González-Calle et al. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients
Janjua et al. Frequency of maintenance hemodialysis patients meeting K/DOQI criteria for serum calcium, phosphorus, calcium phosphorus product and PTH levels; a single institutional experience from Pakistan: a cross sectional study
Kousar et al. A culturally appropriate diet and lifestyle intervention can successfully treat the components of metabolic syndrome in female Pakistani immigrants residing in Melbourne, Australia
Jensen et al. Plasma homocysteine in 80-year-olds: relationships to medical, psychological and social variables
De Souza et al. Rationale and study design of randomized controlled trial of dietary supplementation with prune (dried plums) on bone density, geometry, and estimated bone strength in postmenopausal women: the Prune Study
Uwanuruochi et al. Cardiovascular risk factors in adult staff of Federal Medical Centre, Umuahia: a comparison with other Nigerian studies
Merlini et al. New Clinical and Immunofluorescence Data of Collagen VI-Related Myopathy: A Single Center Cohort of 69 Patients
Behinaein et al. Age and sex influence on bone and blood lead concentrations in a cohort of the general population living in Toronto
Nawawi et al. Type of diabetes and waist–hip ratio are important determinants of serum lipoprotein (a) levels in diabetic patients
Goldberg et al. Influence of demographic factors on serum concentrations of seven chemical constituents in healthy human subjects

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION